“Schizophrenia Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Schizophrenia Market.
The Schizophrenia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Schizophrenia Pipeline Report:
Companies across the globe are diligently working toward developing novel Schizophrenia treatment therapies with a considerable amount of success over the years.
Schizophrenia companies working in the treatment market are Midatech, Addex Therapeutics, Autifony Therapeutics, MapLight Therapeutics, Cyclerion Therapeutics, Valentech LLC, Roche, Merck Sharp & Dohme, Cerevel Therapeutics, Boehringer Ingelheim, Sunovion Pharmaceuticals, Karuna Therapeutics, and others, are developing therapies for the Schizophrenia treatment
Emerging Schizophrenia therapies such as – MTD211, M4 PAM, Back up modulators, ML-007, CY 6463, VLT-015, Ralmitaront, MK-8189, Emraclidine, Iclepertin, Ulotaront, KarXT, and others are expected to have a significant impact on the Schizophrenia market in the coming years.
In August 2023, Sumitomo Pharma revealed disappointing results as two Phase III trials targeting schizophrenia failed to achieve their primary goals. These trials, named DIAMOND 1 and DIAMOND 2, assessed ulotaront’s efficacy in managing acute psychosis among adults diagnosed with schizophrenia. Ulotaront, possessing trace amine-associated receptor 1 (TAAR1) agonist properties alongside 5-HT1A agonist activity, was the focus of investigation. Notably, Otsuka Pharmaceutical collaborates with Sumitomo Pharma in the co-development of this drug candidate.
In March 2023, Positive topline results from the Phase 3 EMERGENT-3 trial, which examined the effectiveness, safety, and tolerability of KarXT (xanomeline-trospium), the company’s flagship experimental medication, in adults with schizophrenia, were released by Karuna Therapeutics
Schizophrenia Overview
Schizophrenia is a chronic and severe mental disorder characterized by disruptions in thought processes, perceptions, emotions, and behavior. People with schizophrenia may experience hallucinations (seeing or hearing things that others do not), delusions (false beliefs), disorganized thinking and speech, reduced expression of emotions, and social withdrawal.
Get a Free Sample PDF Report to know more about Schizophrenia Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/schizophrenia-pipeline-insight
Emerging Schizophrenia Drugs Under Different Phases of Clinical Development Include:
MTD211: Midatech
M4 PAM: Addex Therapeutics
Back up modulators: Autifony Therapeutics
ML-007: MapLight Therapeutics
Luvadaxistat: Takeda
CY6463: Cyclerion Therapeutics
AVP 786: Avanir Pharmaceuticals
CY 6463: Cyclerion Therapeutics
VLT-015: Valentech LLC
Ralmitaront: Roche
MK-8189: Merck Sharp & Dohme
Emraclidine: Cerevel Therapeutics
Iclepertin: Boehringer Ingelheim
Ulotaront: Sunovion Pharmaceuticals
KarXT: Karuna Therapeutics
Route of Administration
Schizophrenia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Inhalation
Inhalation/Intravenous/Oral
Intranasal
Intravenous
Intravenous/ Subcutaneous
NA
Oral
Oral/intranasal/subcutaneous
Parenteral
Subcutaneous
Molecule Type
Products have been categorized under various Molecule types, such as
Antibody
Antisense oligonucleotides
Immunotherapy
Monoclonal antibody
Peptides
Protein
Recombinant protein
Small molecule
Stem Cell
Vaccine
Schizophrenia Pipeline Therapeutics Assessment
Schizophrenia Assessment by Product Type
Schizophrenia By Stage and Product Type
Schizophrenia Assessment by Route of Administration
Schizophrenia By Stage and Route of Administration
Schizophrenia Assessment by Molecule Type
Schizophrenia by Stage and Molecule Type
DelveInsight’s Schizophrenia Report covers around 70+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Further Schizophrenia product details are provided in the report. Download the Schizophrenia pipeline report to learn more about the emerging Schizophrenia therapies
Some of the key companies in the Schizophrenia Therapeutics Market include:
Key companies developing therapies for Schizophrenia are – Otsuka Pharmaceutical Development & Commercialization, Inc., Gedeon Richter Ltd., Lyndra Therapeutics, Neurocrine Bioscience, Takeda Pharmaceutical Company, Memory Pharmaceuticals, Hoffmann-La Roche, Neurocrine Biosciences, Boehringer Ingelheim, Meiji Seika Pharma Co., Ltd., SK Life Science, Inc., Alkermes, Inc. , Solvay Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, SyneuRx International (Taiwan) Corp, BioXcel Therapeutics Inc, Cognitive Research Corporation, Amarex Clinical Research, Forum Pharmaceuticals Inc, Amneal Pharmaceuticals, LLC, Recognify Life Sciences, Accutest Research Laboratories (I) Pvt. Ltd., Eli Lilly and Company, Johnson & Johnson Pharmaceutical Research & Development, L.L.C, Janssen, LP, Delpor, Inc., Jiangsu Hansoh Pharmaceutical, Cerevel Therapeutics, LLC, Zogenix, Inc., Luye Pharma, Reviva Pharmaceuticals, Alkermes, Inc., Karuna Therapeutics, Autifony Therapeutics, Neumora Therapeutics, Adex Therapeutics, and others.
Schizophrenia Pipeline Analysis:
The Schizophrenia pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Schizophrenia with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Schizophrenia Treatment.
Schizophrenia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Schizophrenia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Schizophrenia market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Schizophrenia drugs and therapies
Schizophrenia Pipeline Market Drivers
Emergence of second and third generation anti-phsychotics, increasing need for better and effective treatment are some of the important factors that are fueling the Schizophrenia Market.
Schizophrenia Pipeline Market Barriers
However, lack of understanding of disease etiology and pathophysiology, patent expiry of major drugs and other factors are creating obstacles in the Schizophrenia Market growth.
Scope of Schizophrenia Pipeline Drug Insight
Coverage: Global
Key Schizophrenia Companies: Midatech, Addex Therapeutics, Autifony Therapeutics, MapLight Therapeutics, Cyclerion Therapeutics, Valentech LLC, Roche, Merck Sharp & Dohme, Cerevel Therapeutics, Boehringer Ingelheim, Sunovion Pharmaceuticals, Karuna Therapeutics, and others
Key Schizophrenia Therapies: MTD211, M4 PAM, Back up modulators, ML-007, CY 6463, VLT-015, Ralmitaront, MK-8189, Emraclidine, Iclepertin, Ulotaront, KarXT, and others
Schizophrenia Therapeutic Assessment: Schizophrenia current marketed and Schizophrenia emerging therapies
Schizophrenia Market Dynamics: Schizophrenia market drivers and Schizophrenia market barriers
Request for Sample PDF Report for Schizophrenia Pipeline Assessment and clinical trials
Table of Contents
1
Schizophrenia Report Introduction
2
Schizophrenia Executive Summary
3
4
Schizophrenia- Analytical Perspective In-depth Commercial Assessment
5
Schizophrenia Pipeline Therapeutics
6
Schizophrenia Late Stage Products (Phase II/III)
7
Schizophrenia Mid Stage Products (Phase II)
8
Schizophrenia Early Stage Products (Phase I)
9
Schizophrenia Preclinical Stage Products
10
Schizophrenia Therapeutics Assessment
11
Schizophrenia Inactive Products
12
Company-University Collaborations (Licensing/Partnering) Analysis
13
Schizophrenia Key Companies
14
Schizophrenia Key Products
15
Schizophrenia Unmet Needs
16
Schizophrenia Market Drivers and Barriers
17
Schizophrenia Future Perspectives and Conclusion
18
Schizophrenia Analyst Views
19
Appendix
20
About DelveInsight
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsightContact Person: Gaurav BoraEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/